PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free injection therapy systems, today announced it has entered into convertible debt financing with Mr. Ed Flynn, a private investor, who will be rejoining the Board of Directors. In addition to the funding provided by Mr. Flynn, Bioject’s CEO and other executive officers and a member of the Board are also participating in this round of funding. Pursuant to these agreements, the Company has received or has commitments to receive an aggregate of $615,000.
